Welcome to our dedicated page for Serina Therapeutics SEC filings (Ticker: ser), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Serina Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Serina Therapeutics's regulatory disclosures and financial reporting.
Serina Therapeutics, Inc. reported insider stock transactions by its Chief Scientific Officer on a Form 4. On December 9, 2025, the officer exercised stock options to buy 600 shares of common stock at an exercise price of $0.06 per share, then sold 600 shares at a weighted average price of $3.3133 per share, with individual sale prices ranging from $3.31 to $3.315. On December 10, 2025, the officer similarly exercised options for 645 shares at $0.06 per share and sold 645 shares at $3.35 per share.
The filing shows these transactions as direct ownership and notes that the related stock options, which carry an exercise price of $0.06 and expire on May 6, 2031, are fully vested. After the reported option exercises, the officer holds 370,441 stock options with the same exercise price.
Serina Therapeutics, Inc. reported that it has submitted a complete response to the U.S. Food and Drug Administration’s clinical hold letter for SER-252, its lead program for advanced Parkinson's disease. The company disclosed that the FDA’s clinical hold letter for SER-252 was dated November 25, 2025, and that its response was submitted on December 10, 2025. Serina also issued a press release on this regulatory update, which is included as an exhibit to the report and incorporated by reference.
Serina Therapeutics, Inc. reported transactions by its Chief Scientific Officer involving stock options and common stock in early
After these transactions, the officer reported owning no shares of common stock directly, while continuing to hold 371,686 stock options with an exercise price of
Serina Therapeutics, Inc. (SER)11/25/2025. The officer exercised a stock option to buy 5,965 shares of common stock at an exercise price of $0.06 per share, then sold 5,965 shares of common stock at a weighted average price of $3.9001 per share, with individual sale prices ranging from $3.90 to $3.91.
After these transactions, the officer directly beneficially owned 5,965 shares of common stock and held 378,186 stock options directly. The filing notes that the reported sale price is a weighted average and the officer will provide details of the individual trade prices upon request.
Serina Therapeutics, Inc. reported an insider equity transaction by its Chief Scientific Officer. On 11/24/2025, the officer exercised a stock option to acquire 535 shares of common stock at an exercise price of $0.06 per share and then sold 535 shares of common stock on the same date.
The sale price reported for these shares is a weighted average of $3.935 per share, with individual sales executed at prices ranging from $3.917 to $3.98. Following these transactions, the reporting person holds 384,151 derivative securities in the form of stock options that remain beneficially owned and are fully vested.
Serina Therapeutics, Inc. officer reports option exercise and share sale. The company’s Chief Scientific Officer exercised stock options for 6,500 shares of common stock at an exercise price of $0.06 per share on 11/18/2025. On the same date, 6,500 shares of common stock were sold in an open market transaction at a weighted average price of $3.7541 per share, leaving 0 shares of common stock directly owned after the transaction. The filing also shows that 384,686 stock options with a $0.06 exercise price remained beneficially owned following the reported transactions, and these options are fully vested with an expiration date of 05/06/2031.
Serina Therapeutics furnished an 8-K announcing its financial results for the quarter ended September 30, 2025. The results are provided in a press release attached as Exhibit 99.1.
The company stated this information is furnished, not filed, under the Exchange Act and is not incorporated by reference except as specifically set forth. The filing lists the company’s common stock trading on NYSE American under the symbol SER.
Serina Therapeutics reported Q3 2025 results marked by losses and liquidity pressure. The company posted a net loss of $4.6 million for the quarter and $15.9 million for the nine months ended September 30, 2025, with no Q3 revenue and $0.1 million in grant revenue year to date. Cash and cash equivalents were $8.6 million as of September 30, 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern.
Operating cash outflow was $11.9 million for the nine‑month period. To bolster liquidity, Serina raised capital through a $4.9 million private placement of Series A preferred stock, $2.2 million of net proceeds via an at‑the‑market program, and drew $5.0 million from a new unsecured convertible note that provides up to $20 million across clinical milestones. The FDA placed a clinical hold on the IND for SER‑252 on November 3, 2025, requesting additional information on an excipient. Shares outstanding were 10,664,064 as of November 10, 2025.
Serina Therapeutics (SER) insider transaction: The Chief Scientific Officer exercised stock options for 6,500 shares at $0.06 on 11/10/2025 and sold 6,500 shares of common stock at a weighted average price of $4.10. The filing notes sales occurred in multiple trades between $4.30 and $4.00. Following these transactions, common stock beneficial ownership was 0 shares.
The option exercised was a stock option (right to buy) fully vested, with an expiration date of 05/06/2031. Derivative securities beneficially owned after the reported transactions totaled 391,186 options.
Serina Therapeutics (SER) reported results from its 2025 Annual Meeting held on November 7, 2025. A quorum was present.
Shareholders elected two directors: Steve Ledger (For: 4,165,885; Withheld: 93,287; Broker non-votes: 2,681,141) and Karen J. Wilson (For: 4,169,893; Withheld: 89,279; Broker non-votes: 2,681,141) to serve until the 2028 meeting.
Shareholders ratified Frazier & Deeter, LLC as independent auditor for 2025 (For: 6,544,850; Against: 377,827; Abstain: 17,636). They also approved the issuance of common stock in connection with the exercise of the Convertible Note and Warrants (For: 4,149,038; Against: 108,481; Abstain: 1,653; Broker non-votes: 2,681,141).